CMMB · Chemomab Therapeutics Ltd. American Depositary Share
View on chartInsiders & Stakes
| OrbiMed Israel GP Ltd. 10% Owner | ▼ Sell | Open Market | 2,241,274 Shares held | 1/3/2023 | View profile |
| Peter Thiel Director | ▲ Buy | Open Market | 1,108,509 Shares held | 3/16/2021 | View profile |
| Neil Harris Cohen Director | ▼ Sell | Open Market | 33,000 Shares held | 8/28/2026 | View profile |
| George Adi Mor Chief Scientific Officer | ▼ Sell | Other | 18,750 Shares held | 5/29/2026 | View profile |
| Dale R. Pfost Chief Executive Officer | ▲ Buy | Open Market | 2,500 Shares held | 3/14/2022 | View profile |
| Donald Marvin Executive VP, CFO & COO | ▲ Buy | Open Market | 2,000 Shares held | 3/16/2022 | View profile |
| Joel Michael Maryles Director | ▲ Buy | Open Market | 1,433 Shares held | 5/24/2022 | View profile |
| Nissim Darvish Director | ▲ Buy | Open Market | 1,200 Shares held | 3/11/2022 | View profile |
Transaction History
| Neil Harris Cohen | ▼ Sell | Open Market | 1,000 | $3K | 8/28/2026 |
| Neil Harris Cohen | ▼ Sell | Open Market | 1,304 | $4K | 8/27/2026 |
| George Adi Mor | ▲ Buy | Open Market | 4,878 | $10K | 5/29/2026 |
| George Adi Mor | ▲ Buy | Open Market | 4,926 | $10K | 5/29/2026 |
| George Adi Mor | ▼ Sell | Other | 31,712 | — | 5/29/2026 |
| George Adi Mor | ▼ Sell | Other | 18,750 | — | 5/29/2026 |
| OrbiMed Israel GP Ltd. | ▼ Sell | Open Market | 266,376 | $890K | 1/3/2023 |
| OrbiMed Israel GP Ltd. | ▼ Sell | Open Market | 70,524 | $318K | 1/3/2023 |
| George Adi Mor | ▼ Sell | Open Market | 7,700 | $39K | 1/3/2023 |
| George Adi Mor | ▼ Sell | Open Market | 6,100 | $31K | 1/3/2023 |
| Neil Harris Cohen | ▼ Sell | Open Market | 2,409 | $5K | 11/16/2022 |
| George Adi Mor | ▼ Sell | Open Market | 324,775 | $677K | 11/16/2022 |
| George Adi Mor | ▼ Sell | Open Market | 257,248 | $536K | 11/16/2022 |
| Joel Michael Maryles | ▲ Buy | Open Market | 400 | $1K | 5/24/2022 |
| Joel Michael Maryles | ▲ Buy | Open Market | 33 | $91 | 5/24/2022 |
| Neil Harris Cohen | ▲ Buy | Open Market | 2,000 | $6K | 5/18/2022 |
| Joel Michael Maryles | ▲ Buy | Open Market | 500 | $2K | 3/18/2022 |
| Joel Michael Maryles | ▲ Buy | Open Market | 500 | $2K | 3/18/2022 |
| Donald Marvin | ▲ Buy | Open Market | 250 | $825 | 3/16/2022 |
| Donald Marvin | ▲ Buy | Open Market | 250 | $813 | 3/16/2022 |
| Donald Marvin | ▲ Buy | Open Market | 250 | $1K | 3/14/2022 |
| Donald Marvin | ▲ Buy | Open Market | 250 | $995 | 3/14/2022 |
| Donald Marvin | ▲ Buy | Open Market | 250 | $975 | 3/14/2022 |
| Donald Marvin | ▲ Buy | Open Market | 250 | $1K | 3/14/2022 |
| Donald Marvin | ▲ Buy | Open Market | 250 | $1K | 3/14/2022 |
| Dale R. Pfost | ▲ Buy | Open Market | 1,800 | $7K | 3/14/2022 |
| Dale R. Pfost | ▲ Buy | Open Market | 700 | $3K | 3/14/2022 |
| Neil Harris Cohen | ▲ Buy | Open Market | 2,000 | $8K | 3/14/2022 |
| Neil Harris Cohen | ▲ Buy | Open Market | 2,000 | $9K | 3/14/2022 |
| Neil Harris Cohen | ▲ Buy | Open Market | 2,000 | $9K | 3/14/2022 |
| Nissim Darvish | ▲ Buy | Open Market | 1,200 | $5K | 3/11/2022 |
| Neil Harris Cohen | ▲ Buy | Open Market | 2,000 | $15K | 12/6/2021 |
| Neil Harris Cohen | ▲ Buy | Open Market | 2,409 | $100K | 3/16/2021 |
| OrbiMed Israel GP Ltd. | ▲ Buy | Grant | 288,170 | $5.0M | 3/16/2021 |
| Peter Thiel | ▲ Buy | Open Market | 230,536 | — | 3/16/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Chemomab Amends Merger Agreement for U.S. Redomiciliation
Chemomab has amended its merger agreement to facilitate a U.S. redomiciliation and combination with Scipher. This corporate restructuring is a significant development for the company's structure. The stock is currently trading near its 52-week low, reflecting the ongoing uncertainty surrounding these changes.
Chemomab Amends Merger Agreement for U.S. Redomiciliation. Chemomab has amended its merger agreement to facilitate a U.S. redomiciliation and combination with Scipher. This corporate restructuring is a significant development for the company's structure. The stock is currently trading near its 52-week low, reflecting the ongoing uncertainty surrounding these changes.